133 related articles for article (PubMed ID: 37096337)
21. [Features of the course and adverse events risk of coronavirus infection COVID-19 in hematological diseases (data from the CHRONOS19 register for the Primorsky Territory, intermediate stage)].
Talko AV; Nevzorova VA; Dubov VS; Muzychenko NS; Gurbanov ER; Dubov SK; Beniova SN; Simakova AI
Ter Arkh; 2023 Sep; 95(7):537-542. PubMed ID: 38159002
[TBL] [Abstract][Full Text] [Related]
22. Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies.
Jeyaraman P; Agrawal N; Bhargava R; Bansal D; Ahmed R; Bhurani D; Bansal S; Rastogi N; Borah P; Naithani R;
Transfus Apher Sci; 2021 Jun; 60(3):103075. PubMed ID: 33574010
[TBL] [Abstract][Full Text] [Related]
23. Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany.
Shoumariyeh K; Biavasco F; Ihorst G; Rieg S; Nieters A; Kern WV; Miething C; Duyster J; Engelhardt M; Bertz H
Cancer Med; 2020 Nov; 9(22):8412-8422. PubMed ID: 32931637
[TBL] [Abstract][Full Text] [Related]
24. Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study.
Lanza F; Monaco F; Ciceri F; Cairoli R; Sacchi MV; Guidetti A; Marchetti M; Massaia M; Arcaini L; Krampera M; Mohamed S; Gherlinzoni F; Mecucci C; Gentile M; Romano I; Venditti A; Ruggeri M; Ferrero D; Coviello E; Fabbri E; Corradini P; Passamonti F
Hematol Oncol; 2022 Dec; 40(5):857-863. PubMed ID: 35932208
[TBL] [Abstract][Full Text] [Related]
25. Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis.
Naimi A; Yashmi I; Jebeleh R; Imani Mofrad M; Azimian Abhar S; Jannesar Y; Heidary M; Pakzad R
J Clin Lab Anal; 2022 May; 36(5):e24387. PubMed ID: 35385130
[TBL] [Abstract][Full Text] [Related]
26. COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study.
Węcławek-Tompol J; Zakrzewska Z; Gryniewicz-Kwiatkowska O; Pierlejewski F; Bień E; Zaucha-Prażmo A; Zając-Spychała O; Szmydki-Baran A; Mizia-Malarz A; Bal W; Sawicka-Żukowska M; Kruk A; Ociepa T; Raciborska A; Książek A; Szczepański T; Peregud-Pogorzelski J; Krawczuk-Rybak M; Chaber R; Matysiak M; Wachowiak J; Irga-Jaworska N; Młynarski W; Dembowska-Bagińska B; Balwierz W; Matkowska-Kocjan A; Kazanowska B; Styczyński J; Ussowicz M
J Hematol Oncol; 2021 Oct; 14(1):163. PubMed ID: 34635137
[TBL] [Abstract][Full Text] [Related]
27. Impact of SARS-CoV-2 infection on patients with hematological malignancies: a retrospective study.
Zhao H; He Y; Li Z; Huang Y; Ying Y; Huang Z
Hematology; 2023 Dec; 28(1):2288480. PubMed ID: 38063157
[TBL] [Abstract][Full Text] [Related]
28. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
Guven DC; Sahin TK; Akın S; Uckun FM
Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
[TBL] [Abstract][Full Text] [Related]
29. Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience.
Amanam I; Yao J; Puing A; Tsai NC; Samuels D; Ngo D; Ho S; Ali H; Aribi A; Arslan S; Artz A; Htut M; Koller P; Salhotra A; Sandhu K; Nikolaenko L; Pawlowska A; Shouse G; Stein A; Marcucci G; Forman S; Nakamura R; Dadwal S; Al Malki MM
Cancer Med; 2023 May; 12(10):11248-11253. PubMed ID: 37081733
[TBL] [Abstract][Full Text] [Related]
30. An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.
Shafat T; Grupel D; Porges T; Abuhasira R; Belkin A; Deri O; Oster Y; Zahran S; Horwitz E; Horowitz NA; Khatib H; Batista MV; Cortez AC; Brosh-Nissimov T; Segman Y; Ishay L; Cohen R; Atamna A; Spallone A; Chemaly RF; Ramos-Ramos JC; Chowers M; Rogozin E; Oren NC; Keske Ş; Barchad OW; Nesher L;
Cancer Med; 2024 Feb; 13(3):e6997. PubMed ID: 38400683
[TBL] [Abstract][Full Text] [Related]
31. Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.
Cattaneo C; Cancelli V; Imberti L; Dobbs K; Sottini A; Pagani C; Belotti A; Re A; Anastasia A; Quaresima V; Tucci A; Chiorini JA; Su HC; Cohen JI; Burbelo PD; Rossi G; Notarangelo LD
Blood Cancer J; 2021 Sep; 11(9):151. PubMed ID: 34521813
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
33. Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana.
Lunski MJ; Burton J; Tawagi K; Maslov D; Simenson V; Barr D; Yuan H; Johnson D; Matrana M; Cole J; Larned Z; Moore B
Cancer; 2021 Jan; 127(2):266-274. PubMed ID: 33112411
[TBL] [Abstract][Full Text] [Related]
34. COVID-19 in Patients with Hematologic Disorders Undergoing Therapy: Perspective of a Large Referral Hematology Center in Rome.
Girmenia C; Gentile G; Micozzi A; Petrucci L; Malaspina F; Di Prima A; Baldacci E; Bianchi S; Pugliese P; Turriziani O; Antonelli G; Tombolini V; Foà R; Martelli M
Acta Haematol; 2020; 143(6):574-582. PubMed ID: 32932252
[TBL] [Abstract][Full Text] [Related]
35. When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities.
Wang Q; Berger NA; Xu R
Blood Rev; 2021 May; 47():100775. PubMed ID: 33187811
[TBL] [Abstract][Full Text] [Related]
36. COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research.
Wang L; Kaelber DC; Xu R; Berger NA
Blood Rev; 2022 Jul; 54():100931. PubMed ID: 35120771
[TBL] [Abstract][Full Text] [Related]
37. COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry.
Borno HT; Kim MO; Hong JC; Yousefi S; Lin A; Tolstykh I; Zhang S; McKay RR; Harismendy O; Cinar P; Rugo H; Koshkin VS; Rabow M; Wang C; Bailey A; Small EJ
Oncologist; 2022 May; 27(5):398-406. PubMed ID: 35348771
[TBL] [Abstract][Full Text] [Related]
38. Predictors of clinical evolution of SARS-CoV-2 infection in hematological patients: A systematic review and meta-analysis.
Carrara E; Razzaboni E; Azzini AM; De Rui ME; Pinho Guedes MN; Gorska A; Giannella M; Bussini L; Bartoletti M; Arbizzani F; Palacios-Baena ZR; Caponcello G; Maldonado N; Rodríguez-Baño J; Visco C; Krampera M; Tacconelli E
Hematol Oncol; 2023 Feb; 41(1):16-25. PubMed ID: 36238977
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics, therapeutic management, and prognostic factors of adult COVID-19 inpatients with hematological malignancies.
Wu Y; Chen W; Li W; Zhao M; Wei Q; Zhang X; Mei H; Wang Y; Hu Y
Leuk Lymphoma; 2020 Dec; 61(14):3440-3450. PubMed ID: 32840399
[TBL] [Abstract][Full Text] [Related]
40. [Features of COVID-19 infection among patients with hematological malignancies].
Fissore G; Skog S; Lastra J; Chandía M
Rev Med Chil; 2022 May; 150(5):625-633. PubMed ID: 37906763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
